文献速递消化系统肿瘤

高危II期结直肠癌辅助双药化疗3个月与6个月疗程比较

Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer.
PubMed 文献 · J Clin Oncol · 2021-01-13

基于IDEA协作中4项研究,3273例高危II期结肠或直肠癌患者随机接受3个月或6个月FOLFOX或CAPOX辅助化疗。5年无病生存率3个月组80.7%、6个月组83.9%(HR 1.17;80%CI 1.05-1.31;CAPOX亚组HR 1.02(80%CI 0.88-1.17),FOLFOX亚组HR 1.41(80%CI 1.18-1.68)。

要点

  • 高危II期结直肠癌总体人群3个月辅助化疗未证明非劣效于6个月。
  • CAPOX方案3个月与6个月疗效接近(HR 1.02),FOLFOX方案3个月疗效较差(HR 1.41)。
  • 若适合奥沙利铂方案,3个月CAPOX可作为高危II期结肠癌的潜在选择。

核心结论

  • 总体人群未证明3个月辅助化疗非劣效于6个月,但3个月CAPOX因便利、毒性低和成本低可作为高危II期结肠癌的潜在选项。

研究设计与样本

  • IDEA协作中4项研究纳入高危II期结肠和直肠癌患者,随机分配至3个月或6个月FOLFOX或CAPOX治疗。
  • 共3273例合格患者入组,62%接受CAPOX,38%接受FOLFOX。
  • 主要终点为无病生存(DFS),非劣效界值为HR<1.2,需542个DFS事件,80%把握度,单侧一类错误率0.10。

主要发现

  • CAPOX亚组HR为1.02(80%CI 0.88-1.17),FOLFOX亚组HR为1.41(80%CI 1.18-1.68)。
  • 疗程效应似乎依赖化疗方案,尽管交互作用检验为阴性。

关键数值与推荐

  • 非劣效定义:3个月组相对6个月组的DFS风险比HR<1.2。
  • CAPOX亚组HR 1.02(80%CI 0.88-1.17);FOLFOX亚组HR 1.41(80%CI 1.18-1.68)。

临床怎么用

  • 高危II期结肠癌若适合奥沙利铂方案,可考虑3个月CAPOX辅助化疗以降低毒性、便利和节约成本。
  • FOLFOX方案3个月疗程疗效较差,不宜常规缩短。
  • 高危II期定义中各因素的相对贡献需进一步研究以指导个体化疗程选择。

局限性

  • 总体人群未达到非劣效性,3个月疗程不能普遍推荐。
  • 疗程效应与化疗方案的交互作用检验为阴性,亚组结果需谨慎解读。
  • 高危II期定义因素的相对贡献尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: As oxaliplatin results in cumulative neurotoxicity, reducing treatment duration without loss of efficacy would benefit patients and healthcare providers. PATIENTS AND METHODS: Four of the six studies in the International Duration of Adjuvant Chemotherapy (IDEA) collaboration included patients with high-risk stage II colon and rectal cancers. Patients were treated (clinician and/or patient choice) with either fluorouracil, leucovorin, and oxaliplatin (FOLFOX) or capecitabine and oxaliplatin (CAPOX) and randomly assigned to receive 3- or 6-month treatment. The primary end point is disease-free survival (DFS), and noninferiority of 3-month treatment was defined as a hazard ratio (HR) of < 1.2- v 6-month arm. To detect this with 80% power at a one-sided type one error rate of 0.10, a total of 542 DFS events were required. RESULTS: 3,273 eligible patients were randomly assigned to either 3- or 6-month treatment with 62% receiving CAPOX and 38% FOLFOX. There were 553 DFS events. Five-year DFS was 80.7% and 83.9% for 3-month and 6-month treatment, respectively (HR, 1.17; 80% CI, 1.05 to 1.31; P [for noninferiority] .39). This crossed the noninferiority limit of 1.2. As in the IDEA stage III analysis, the duration effect appeared dependent on the chemotherapy regimen although a test of interaction was negative. HR for CAPOX was 1.02 (80% CI, 0.88 to 1.17), and HR for FOLFOX was 1.41 (80% CI, 1.18 to 1.68). CONCLUSION: Although noninferiority has not been demonstrated in the overall population, the convenience, reduced toxicity, and cost of 3-month adjuvant CAPOX suggest it as a potential option for high-risk stage II colon cancer if oxaliplatin-based chemotherapy is suitable. The relative contribution of the factors used to define high-risk stage II disease needs better understanding.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Iveson TJ, Sobrero AF, Yoshino T, et al. Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer. J Clin Oncol. 2021. PMID: 33439695. doi:10.1200/JCO.20.01330

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。